Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

Phase 2

Completed

• Conditions: Osteoarthritis of the Knee
• Interventions: Drug: Bone morphogenetic protein 7; Drug: Placebo

• Registration Number: NCT01111045
• Lead Sponsor: Stryker Biotech

Brief Summary

The objectives of the study are to evaluate the safety and efficacy of intraarticular BMP-7 for the treatment of osteoarthritis of the knee.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-04
• Study First Submitted: 2010-04-23
• Study First Submitted QC: 2010-04-26
• Study First Posted: 2010-04-27
• Primary Completion: 2011-08
• Study Completion: 2011-08
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-30
• Last Update Posted: 2012-02-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 355

Inclusion Criteria

• Ambulatory with a diagnosis of OA of the knee with symptoms for at least 6 months and pain on the majority of days in the last 30 days. Symptoms must include knee joint pain.
• A male or female adult age >40 years
• female subjects of childbearing potential must have a negative serum pregnancy test during screening and a negative urine pregnancy test on the day of injection
• Radiographic evidence of at least one tibiofemoral osteophyte and Osteoarthritis Research Society International (OARSI) Atlas joint space narrowing grade of 1 or 2 in the index knee
• WOMAC pain score of >8 at screening and baseline
• Able to comply with the study and give informed consent
• Able to read, write and understand English

Exclusion Criteria

• A requirement for treatment with opioids for pain relief.

• Unwilling to abstain from NSAIDs and/or other analgesic medications for 48 hours and acetaminophen for 24 hours prior to pain assessments during the study. Subjects taking low dose aspirin for cardiovascular health may remain on their stable dose throughout the study.

• Using a handicap assistance device (i.e., cane, walker) >50% of the time.

• Undergoing new physical therapy or participating in a weight loss or exercise program that has not been stable for at least 3 months prior to screening visit 1 and will not remain stable during their participation in the study.

• History of arthroscopic or open surgery to the index knee in the past 12 months or planned surgery during study.

• History of joint replacement surgery (index knee).

• Received corticosteroid, short acting hyaluronic acid, or other intraarticular injections of the index knee within 3 months of screening and/or not willing to abstain from treatments for the duration of the study

• Received long acting hyaluronic acid injection of the index knee within 6 months of screening and/or not willing to abstain from treatments for the duration of the study.

• History in the past 10 years of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, amyloidosis or fibromyalgia.

• Clinical signs and symptoms of active knee infection or radiographic evidence of crystal disease other than chondrocalcinosis (i.e., gout and CPPD).

• A history of abnormal laboratory results ≥2.5 x ULN indicative of any significant medical disease, which in the opinion of the investigator, would preclude the subjects participation in the study

• Any of the following abnormal laboratory results during screening:

  1. ALT and AST ≥2.5x ULN
  2. Hemoglobin <11.5 g/dL (Female) or <13.2 g/dL (Male)
  3. WBC <3500 cells/mm3
  4. Lymphocyte count ≤1000 cells/mm3
  5. Serum creatinine ≥1.5 x ULN
  6. Platelet count below the central laboratory lower limit of normal.

• History of malignancy in the past ten years (<10 years), with the exception of resected basal cell, squamous cell of the skin, resected cervical atypia or carcinoma in situ.

• Significant hip pain, ipsilateral to the index knee that may interfere with assessments of index knee pain

• Skin breakdown at the knee where the injection would take place

• A known or clinically suspected infection with human immunodeficiency virus (HIV), or hepatitis C or B viruses

• Participated within 3 months or will participate concurrently in another investigational drug or vaccine study

• A history of drug or alcohol dependence or abuse in the past 3 years

• Previous treatment with BMP-7 or any bone morphogenetic protein

• A female with reproductive capability who is unwilling to use birth control for the duration of the study and/or intends to conceive within 12 months of dosing.

• Other serious, non-malignant, significant, acute or chronic medical or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm 3	Bone morphogenetic protein 7	0.3 mg/ml BMP-7, single intraarticular knee injection
Arm 4	Placebo	1 ml placebo, single intraarticular knee injection (control)
Arm 1	Bone morphogenetic protein 7	0.03 mg/ml BMP-7, single intraarticular knee injection
Arm 2	Bone morphogenetic protein 7	0.1 mg/ml BMP-7, single intraarticular knee injection

Primary Outcome Measures

Name	Time	Method
Change from baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale.	Baseline, and at 24 weeks

Trial Locations

Locations (25)

Boulder Medical Center, PC; 🇺🇸 Boulder, Colorado, United States

Johns Hopkins Medical Center; 🇺🇸 Baltimore, Maryland, United States

Rheumatology Associates; 🇺🇸 Stuart, Florida, United States

University of Arizona Arthritis Center; 🇺🇸 Tucson, Arizona, United States

The Arthritis Center; 🇺🇸 Palm Harbor, Florida, United States

Billings Clinic; 🇺🇸 Billings, Montana, United States

Arthritis and Osteoporosis Center of Maryland; 🇺🇸 Frederick, Maryland, United States

Klein & Associates, MD, PA; 🇺🇸 Cumberland, Maryland, United States

Rheumatology Associates of S. Florida; 🇺🇸 Boca Raton, Florida, United States

David R. Mandel, MD, Inc.; 🇺🇸 Mayfield Village, Ohio, United States

Altoona Center for Clinical Research; 🇺🇸 Duncansville, Pennsylvania, United States

Northwestern Center for Clinical Research; 🇺🇸 Chicago, Illinois, United States

Arizona Arthritis and Rheumatology Research; 🇺🇸 Glendale, Arizona, United States

Baylor Research Institute; 🇺🇸 Dallas, Texas, United States

Clinical Research Center of Reading; 🇺🇸 West Reading, Pennsylvania, United States

Houston Medical Research Associates; 🇺🇸 Houston, Texas, United States

Houston Institute for Clinical Research; 🇺🇸 Houston, Texas, United States

The Center for Pharmaceutical Research, PC; 🇺🇸 Kansas City, Missouri, United States

The Ohio State University Medical Center; 🇺🇸 Columbus, Ohio, United States

Tacoma Center for Arthritis Research; 🇺🇸 Tacoma, Washington, United States

Stanford University School of Medicine; 🇺🇸 Palo Alto, California, United States

UC Davis Medical Center, Center for Aging; 🇺🇸 Sacramento, California, United States

Robin Dore, MD, Inc; 🇺🇸 Tustin, California, United States

Apex Medical Research, AMR, Inc; 🇺🇸 Chicago, Illinois, United States

Illinois Bone and Joint Institute; 🇺🇸 Morton Grove, Illinois, United States